发明名称 |
Antisense Oligonucleotides Against Neutral Sphingomyelinase and Neutral Sphingomyelinase Inhibitor GW4869 for Degenerative Neurological Disorders |
摘要 |
Alzheimer's disease (AD) is the most common human neurodegenerative disease of the CNS resulting in progressive neuronal death and memory loss. Despite intense investigations, no effective therapy is available to stop its onset or halt its progression. It was discovered that antisense oligonucleotide against neutral sphingomyelinase and GW4869, a chemical inhibitor of neutral sphingomyelinase, inhibit activation of glial cells and protect neurons in AD cell culture and animal models. These results suggest the following new treatment options for AD patients: Antisense oligonucleotide against neutral sphingomyelinase and GW4869. |
申请公布号 |
US2016208267(A1) |
申请公布日期 |
2016.07.21 |
申请号 |
US201615017236 |
申请日期 |
2016.02.05 |
申请人 |
Rush University Medical Center |
发明人 |
Pahan Kalipada |
分类号 |
C12N15/113;A61K31/713;A61K31/4178 |
主分类号 |
C12N15/113 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating neurodegenerative disorders in a mammal in need thereof, the method comprising:
administering a composition comprising an inhibitor of neutral sphingomyelinase, the inhibitor comprising an antisense oligonucleotide against neutral sphingomyelinase or GW4869 or an antisense oligonucleotide against neutral sphingomyelinase and GW4869 to the mammal in need thereof to treat the neurodegenerative disorder. |
地址 |
Chicago IL US |